# A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease

> **NIH NIH R43** · CRESTONE, INC. · 2023 · $295,763

## Abstract

ABSTRACT
Allogeneic hematopoietic cell transplantation (allo-HSCT) is an effective therapy for a number of malignant and
non- malignant blood and metabolic diseases, but its applicability has been limited by graft-versus-host disease
(GvHD). GvHD is responsible for 15-30% of deaths that occur following HSCT and is the main cause of morbidity
in up to 50% of recipients. Current prevention and treatment of GvHD remains suboptimal and relies mainly on
corticosteroids and the broad suppression of T cells. This profound immunosuppression can lead to tumor
relapse and infectious complications contributing to a poor quality of life and high mortality in these patients.
Increasing evidence suggests that the patients gut microbiota plays an important role in the development of
acute GvHD. Enterococcus faecalis and Enterococcus faecium dominate the gut microflora of a substantial
portion of allo-HSCT patients after transplant, and this abnormal expansion can precede bloodstream infections.
The goal of this proposal is to evaluate the effect of CRS3123 on the prevention and treatment of acute GvHD
in allo-HSCT. CRS3123 is a highly effective narrow spectrum antibacterial agent, developed by Crestone, Inc,
with a novel mechanism of action that selectively targets bacterial methionyl-tRNA synthetase (MetRS) thereby
inhibiting protein synthesis and bacterial growth. CRS3123 potently inhibits Enterococcus faecalis and
Enterococcus faecium, including vancomycin-resistant strains. It remains largely in the gut after oral dosing
which ensures high intestinal concentrations and limits systemic exposure. Importantly, CRS3123 shows minimal
disruption of most bacterial phyla and largely spares the beneficial gut microbiota. We hypothesize that selective
suppression of pathogenic enterococci overgrowth in the gut by CRS3123 would reduce the occurrence of GvHD
and related outcomes following allo-HSCT without affecting the healthy gut microbiome. To test this hypothesis,
we will evaluate the in vitro and in vivo activity of CRS3123 against enterococci in Specific Aim 1 and determine
CRS3123 efficacy in a murine model of GvHD in Specific Aim 2. These proposed studies will form the basis for
future clinical trials targeting the enterococci domination of the intestinal microbiota to prevent or treat acute
GvHD and transplant-related mortality.

## Key facts

- **NIH application ID:** 10759657
- **Project number:** 1R43AI179346-01
- **Recipient organization:** CRESTONE, INC.
- **Principal Investigator:** CLIFFORD W MASON
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $295,763
- **Award type:** 1
- **Project period:** 2023-08-02 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10759657

## Citation

> US National Institutes of Health, RePORTER application 10759657, A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease (1R43AI179346-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10759657. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*